Innovation is the soul of the survival anddevelopment of enterprises. Anhui Biochem has now determined its corporate R & D strategy with AIDS and hepatitis B preparations as its core and gene cell targeted anti-tumor drug development as its focus. At present, the company is researching more than 20 varieties, involving innovative drugs in the fields of hepatitis B, AIDS, nerves, tumors and tuberculosis.

Over the years, Anhui Biochem has successfully created a strong technical research team, with a total of more than 70 R & D personnel, including 1 national leader in 10,000 people, 1 provincial talent in 100 people, 8 doctors, 32 masters, and senior returnees 5 professors, the expert team covers the fields of applied chemistry, chiral pharmacy, gene cells, drug analysis and testing, etc., and has formed a complete drug development and management system from raw drug to formulation development, registration, and product development and management for the company's products. Rapid development has made outstanding contributions.

In the future, Anhui Biochem will continue to focus on the field of AIDS and hepatitis B treatment, with the strategic R & D thinking of producing one generation, R & D one, reserve one, and eliminating one generation of products, and increase the research and development of various compound preparations and innovative unilateral preparations. At the same time, we are committed to completing the secondary layout and adjustment of the product chain within 5 years, continuously enriching the company's product chain structure, increasing the research and development of gastrointestinal drugs, senile neurological drugs and tumor drugs.

The continuous increase of investment in research and development is a comprehensive display of the company's soft power and hard power

The company has become a national technology center, a national post-doctoral workstation, a secondary gene cell synthesis laboratory, a chiral pharmaceutical engineering center, and a provincial key laboratory. Anhui Biochem has formed a relatively sound medical research and development technology innovation system. It has adopted a two-pronged approach of talent introduction and equipment investment. It has successively purchased and introduced internationally advanced R & D instruments and equipment with a total value exceeding 50 million.

Many years of research funding have reached 10-12% of sales, ranking the forefront of domestic pharmaceutical companies.

Strong enterprises with independent intellectual property rights inject innovation

A professional R & D platform, an advanced national enterprise technology center, equipped with international advanced experimental and analytical instruments, a sound R & D management system and quality management system, Anhui Biochem has 81 patent applications, including 26 invention patents. , Chaired the formulation of 7 national standards. 2 national-level innovation fund projects, 2 national invention patent excellence awards, 1 provincial invention patent gold award, 1 provincial invention patent excellence award, 10 high-tech product certifications, and 1 Anhui provincial science and technology progress first prize . Anhui Biochem has established a complete intellectual property management standard system and passed national certification certification. It has obtained patent licenses in 116 countries for 7 AIDS drugs through the World Drug Patent Pool. Property model enterprises.